{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc:rybrevant:2 retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahc%3Arybrevant%3A2",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00159,
    "timestamp_received": "2026-11-09T16:11:43.312343Z",
    "timestamp_returned": "2026-11-09T16:11:43.313933Z",
    "trace_id": "14c26acd-dd90-4bee-a6a1-b3db398a3715"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hc:rybrevant:2",
      "type": "Indication",
      "description": "RYBREVANT (amivantamab for injection) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-30:0",
          "type": "Contribution",
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hc:rybrevant",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Rybrevant (amivantamab-vmjw) [product monograph]. HC.",
          "title": null,
          "aliases": [],
          "description": "Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083161.PDF. Revised January 2026. Accessed April 2026.",
          "urls": [
            "https://pdf.hres.ca/dpd_pm/00083161.PDF",
            "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101529"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hc",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Canada",
                "description": "Regulatory agency that approves drugs for sale and use in Canada."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Rybrevant",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "amivantamab-vmjw",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2022-03-30",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2026-01-12",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.",
          "description": "The description text for all Statements derived from this Indication."
        }
      ]
    }
  ]
}